Intellia Therapeutics (NTLA) PT Raised to $137 at Wedbush, Following Earnings
Tweet Send to a Friend
Wedbush analyst David Nierengarten raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $137.00 (from $130.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
